HHS Shields Three Ebola Vaccine Makers From Legal Liability
This article was originally published in The Pink Sheet Daily
GlaxoSmithKline, NewLink Genetics and Johnson & Johnson gain protection for their candidate Ebola vaccines; NewLink teams up with Merck, and GSK prepares for Phase II/III studies in West Africa.
You may also be interested in...
HHS asked Federal Register Office to withdraw declaration providing liability immunity to Zika vaccine manufacturers and notice delegating authority under the Cures Act to refine the clinical trials data registry.
FDA officials explain why randomized clinical trials of Ebola products are necessary and the Senate passes Ebola priority review voucher bill. Lilly/AstraZeneca start Alzeimer’s trial, Incyte gains new approval for Jakafi, Sunovion files for new use of Aptiom and AstraZeneca resubmits its once withdrawn lung cancer drug Iressa.
Stakeholders suggest a variety of USPTO and FDA actions that could help ensure patents do not improperly delay generic and biosimilar competition.